Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)

NEXT STORY
FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
PREV STORY
Augustus Labs gets accreditation from the College of American Pathologists.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

author_avatar
NASDAQ Market News

RNA Disease Diagnostics Announces University of Maryland School of Medicine Laboratory Secures FDA Registration and Approval as Development Site for Antisense COVID-19 Test

author_avatar
NASDAQ Market News

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions

author_avatar
NASDAQ Market News